Intranasal desmopressin (DDAVP, DDVP, Minirin, Stimate Nasal Spray) is no longer indicated for primary nocturnal enuresis and is associated with an increased risk of severe hyponatremia (possibly ...
DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
ET-600 matched the pharmacokinetics of the FDA-approved reference product in a study with 75 subjects. Eton expects to submit an NDA for ET-600 in April 2025, targeting a 2026 launch. Today's manic ...
(RTTNews) - Eton Pharmaceuticals, Inc (ETON) Tuesday said that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ET-600, a proprietary desmopressin ...
WASHINGTON, Dec 4 (Reuters) - U.S. health officials alerted the public on Tuesday about the deaths of two patients who were treated with a prescription drug to control bed-wetting. The Food and Drug ...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched desmopressin acetate for injection, which is a generic of Ferring Pharmaceutical’s DDAVP ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback